Do I need to be tested for genetic mutations while taking nintedanib?

Nintedanib (Nintedanib) is a targeted drug mainly used to treat certain types of lung diseases, including idiopathic pulmonary fibrosis (IPF) and certain interstitial lung diseases. The need for genetic mutation testing before using nintedanib depends on the specific clinical situation and the patient's disease type.

Nintedanib is mainly used for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related interstitial lung disease (SSc-ILD) and certain types of advanced non-small cell lung cancer. The cause of idiopathic pulmonary fibrosis is complex and involves environmental factors and genetic factors, but there is currently a lack of specific gene mutation markers for this disease. Studies have shown that nintedanib can slow down the decline of lung function. Therefore, for these patients, the drug can be used without genetic testing. Doctors usually evaluate the patient's condition based on clinical symptoms, imaging examinations and pulmonary function tests, and decide whether to use nintedanib.

However, for the treatment of non-small cell lung cancer, the use of nintedanib is different. It is often used in combination with other therapies and is generally used in patients who have received prior chemotherapy and do not have epidermal growth factor receptor (EGFR) or ALK gene rearrangements. In this case, although the use of nintedanib is not directly dependent on a specific genetic mutation, the patient's overall genetic profile and treatment history may influence the development of treatment options. Therefore, before treatment, doctors may consider the patient's genetic test results, medical history, and condition to develop the most appropriate treatment plan.

In addition, the therapeutic effect of nintedanib is related to individual differences among patients, including age, gender, comorbidities, and disease progression. Therefore, in clinical practice, doctors usually consider multiple factors rather than relying solely on genetic test results. This personalized treatment plan is more in line with the current development direction of medicine.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4742925/